跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2007-000739-25-ES
EUCTR2007-000739-25-ES进行中（未招募）不适用

Estudio multicéntrico, aleatorizado, ciego, de eficacia y seguridad de pasireotida LAR frente a octreotida LAR, en pacientes con tumores carcinoides metastásicos cuyos síntomas relacionados con la enfermedad no están suficientemente controlados con análogos de la somatostatina

ovartis Farmaceutica, S.A0 个研究点目标入组 202 人开始时间: 2008年9月26日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
入组人数
202
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •? Male or female patients aged 18 years or greater.
  • •? Patients with histopathologically confirmed (from primary or metastatic lesion biopsy) metastatic carcinoid tumors of the digestive system with extent of disease determined by Computer Tomography (CT) scan or Magnetic Resonance Imaging (MRI).
  • •? Symptoms of carcinoid disease, diarrhea and flushing, must be inadequately controlled:
  • •Inadequate control: a daily mean of 4 or more bowel movements over a two week period and a total of 5 or more flushing episodes during this period, while receiving the highest recommended dose of one of the following somatostatin analogues:
  • •? octreotide LAR (= 30 mg q 28 days)
  • •? octreotide s.c. (= 600 ?g total daily dose)
  • •? lanreotide Autogel (= 120 mg q 28 days)
  • •? lanreotide SR (= 30 mg q 14 days)
  • •? Patients with measurable or evaluable disease per RECIST criteria (see Post-text
  • •supplement 1)
  • •? Karnofsky Performance Status ? 60 (Requires occasional assistance, but is able to care for most of his personal needs, or better)
  • •? Patients must complete the following washout periods before randomization:
  • •? octreotide LAR, lanreotide autogel or any other long-acting somatostatin analogues: 8 weeks
  • •? lanreotide SR: 4 weeks
  • •? prescription oral opioids: 5 days
  • •? octreotide s.c., other short-acting somatostatin analogues or any other antidiarrheals: 48 hours
  • •Note that during the washout period for long-acting somatostatin analogues, octreotide s.c. or any other short-acting antidiarrheal agents may be administered after the baseline symptoms have been collected. However these are not to be taken during the last 48 hours of the washout period prior to randomization.
  • •? Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary (see Section 6.6.2.1)
  • •? Female patients of child bearing potential must have a negative pregnancy test at baseline.
  • •? Patients for whom written informed consent to participate in the study has been obtained
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •?Patients receiving radiolabeled somatostatin analogue therapy within the 6 months or any
  • •cytotoxic chemotherapy or interferon therapy within the 2 months prior to recording
  • •baseline symptoms
  • •? Patients who have undergone major surgery/surgical therapy for any cause within 1 month
  • •or surgical therapy of loco-regional metastases within the last 3 months before recording
  • •baseline symptoms
  • •? Patients with hepatic artery embolization within the last 6 months (1 month if there are
  • •other sites of measurable disease), or patients who have undergone cryoablation or
  • •radiofrequency ablation of hepatic metastasis within the last 2 months before recording
  • •baseline symptoms
  • •? Patients who have received radiotherapy for any reason within the last 4 weeks must have
  • •recovered from any side effects of radiotherapy before recording baseline symptoms
  • •? Patients who are unwilling to follow dietary restrictions (see Section 7.4.2.7) within 3
  • •days of urinary 5-HIAA sample collection or require medications that would interfere with
  • •urinary 5-HIAA measurement (e.g. Reserpine, mephenesin carbamate, Lugol?s solution)
  • •? Patients with malabsorption syndrome, short bowel or chologenic diarrhea not controlled
  • •by specific therapeutic means
  • •? Patients who are not biochemically euthyroid
  • •? Diabetic patients on antidiabetic medications whose fasting blood glucose is poorly
  • •controlled as indicated by HbA1C > 8%
  • •? Patients with symptomatic cholelithiasis
  • •? Patients who have congestive heart failure (NYHA Class III or IV), unstable angina,
  • •sustained ventricular tachycardia, ventricular fibrillation, clinically significant
  • •bradycardia, advanced heart block or a history of acute myocardial infarction within the
  • •six months preceding enrollment
  • •? Patients with risk factors for torsades de pointes, i.e. patients with a baseline QTc > 450
  • •ms, hypokalemia, hypomagnesemia, hypocalcemia, family history of long QT syndrome,
  • •and concomitant medications known to prolong the QT interval
  • •? Patients with liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
  • •hepatitis with serum creatinine > 2.0 X ULN, serum bilirubin > 2 X ULN, serum albumin
  • •< 0.67 X LLN, and/or ALT or AST more than 2 X ULN for patients without liver
  • •metastases or ALT or AST more than 5X ULN for patients with documented liver
  • •? Patients with additional active malignant disease within the last five years (with the
  • •exception of basal cell carcinoma or carcinoma in situ of the cervix)
  • •? Patients with the presence of active or suspected acute or chronic uncontrolled infection or
  • •with a history of immunocompromise, including a positive HIV test result (ELISA and
  • •Western blot). A HIV test will not be required; however, previous medical history will be
  • •? Patients with abnormal coagulation (PT or APTT elevated by 30% above normal limits) or
  • •patients receiving anticoagulants that affect PT (prothrombin time) or APTT ( activated
  • •thromboplastin time)
  • •? Patients with WBC <2.5 X 109/L; Hgb <10 g/dL; PLT <100 X 109/L
  • •? Patients who have any current or prior medical condition that may interfere with the
  • •conduct of the study or the evaluation of its results in the opinion of the Investigator or the
  • •Sponsor?s Medical Monitor
  • •? Female patients who are pregnant or lactating, or are of childbearing potential and not
  • •practicing a medically acceptable method of birth control. Female patients must use
  • •barrier contraception with condoms. If oral contraception is used in addition to condoms,

研究者

发起方
ovartis Farmaceutica, S.A

相似试验

进行中（未招募）
1 期
Estudio multicéntrico, aleatorizado y ciego para evaluar la seguridad y la eficacia de pasireotida LAR frente a octreotida LAR, en pacientes con acromegalia activaa acromegalia se caracteriza por una hipersecreción crónica de GH (hormona de crecimiento), manifestaciones clínicas debidas a las acciones periféricas del exceso de GH y de concentraciones elevadas de IGF-I y/o al efecto de la masa tumoral local en prácticamente todos los órganos. La enfermedad cardiovascular es la principal causa de morbilidad e incrementa la mortalidad.MedDRA version: 9.1Level: LLTClassification code 10000599Term: Acromegaly
EUCTR2007-001972-36-ESovartis Farmacéutica, S. A330
进行中（未招募）
不适用
Estudio multicéntrico, aleatorizado, ciego, controlado con placebo de 3 meses de duración para evaluar el efecto del tratamiento con fingolimod en la respuesta inmune después de la vacuna para la gripe estacional y la dosis de recuerdo de vacuna antitetánica en pacientes con formas recidivantes de esclerosis múltipleFormas recurrentes de esclerosis múltipleMedDRA version: 13Level: PTClassification code 10048393Term: Recidiva de esclerosis múltiple
EUCTR2010-019028-30-ESovartis Farmacéutica, S.A.120
进行中（未招募）
不适用
Estudio multicéntrico, aleatorizado, ciego, doble simulación, con control placebo, tres periodos, cruzado, para evaluar el efecto del QVA149 (110/50 µg o.d.) en la resistencia al ejercicio en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) moderada a severa, utilizando tiotropio como control activo.
EUCTR2010-022721-14-ESovartis Farmaceutica, S.A.80
进行中（未招募）
不适用
Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para determinar la eficacia y la seguridad de la albiglutida administrada en combinación con pioglitazona, con o sin metformina, en sujetos con diabetes mellitus de tipo 2.A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes MellitusDiabetes mellitus de tipo 2Type 2 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
EUCTR2008-007662-37-ESGlaxoSmithKline Research and Development Ltd.300
进行中（未招募）
1 期
Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, de control activo, de 14 semanas de duración para evaluar la efectividad de la estrategia de tratamiento de valsartan con respecto a amlodipino para alcanzar un control de la presión arterial en pacientes con hipertensión grado l o grado 2 o no controlada actualmente en monoterapia.Essential hypertension
EUCTR2005-000684-26-ESovartis Farmacéutica S.A